HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nordström, E. K. L. Articles by Liljeström, P. Search for Related Content PubMed PubMed Citation Articles by Nordström, E. K. L. Articles by Liljeström, P. Agricola Articles by Nordström, E. K. L. Articles by Liljeström, P.

Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1

Eva K. L. Nordström^1,2,

Mattias N. E. Forsell^1,2,

¹ Microbiology and Tumor Biology Center, Karolinska Institute, S-171 77 Stockholm, Sweden
² Department of Vaccine Research, Swedish Institute for Infectious Disease Control, S-171 82 Solna, Sweden
³ MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, Oxford, UK

Correspondence
Gunilla B. Karlsson
Nilla.Karlsson{at}mtc.ki.se

With the human immunodeficiency virus type 1 (HIV-1) epidemic expanding at increasing speed, development of a safe and effective vaccine remains a high priority. One of the most central vaccine platforms considered is plasmid DNA. However, high doses of DNA and several immunizations are typically needed to achieve detectable T-cell responses. In this study, a Semliki Forest virus replicon DNA vaccine designed for human clinical trials, DREP.HIVA, encoding an antigen that is currently being used in human trials in the context of a conventional DNA plasmid, pTHr.HIVA, was generated. It was shown that a single immunization of DREP.HIVA stimulated HIV-1-specific T-cell responses in mice, suggesting that the poor immunogenicity of conventional DNA vaccines may be enhanced by using viral replicon-based plasmid systems. The results presented here support the evaluation of Semliki Forest virus replicon DNA vaccines in non-human primates and in clinical studies.

These authors contributed equally.

This article has been cited by other articles:

				A. Morner, I. Douagi, M. N. E. Forsell, C. Sundling, P. Dosenovic, S. O'Dell, B. Dey, P. D. Kwong, G. Voss, R. Thorstensson, et al. Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein J. Virol., January 15, 2009; 83(2): 540 - 551. [Abstract] [Full Text] [PDF]

				T. Hanke, A. J. McMichael, and L. Dorrell Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction J. Gen. Virol., January 1, 2007; 88(1): 1 - 12. [Abstract] [Full Text] [PDF]